Health Care · Pharmaceutical Preparations

NVCT Nuvectis Pharma, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 187555847 filings
Russell 2000

NVCT at a glance

Nuvectis Pharma, Inc. (NVCT, SEC CIK 1875558) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as August 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 17 institutional investment managers tracked by SignalX reported holding Nuvectis Pharma, Inc. (NVCT) shares worth $68.0 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Mosseri Marlio Charles on June 30, 2026 of 50,000 shares at $18.32 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
17 funds
$68.0M · +0 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New risk: U.S. trade-policy changes affecting China-originated NXP100 and NXP200 materials, technology, and clinical data
  • New risk: Tariffs could increase research costs, although no tariffs affected operations as of September 30, 2026
  • Regulatory risk: One Big Beautiful Bill Act FDA workforce reductions could delay product approvals
  • Operational risk: Dependence on Haisco for NXP100 and NXP200 technology transfer and material supply
  • Financial risk: Accumulated deficit reached $142.8 million through September 30, 2026, requiring substantial additional funding

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product revenue since inception
  • Net loss $30.1M vs $7.5M YoY, operating loss $31.0M vs $7.8M
  • Worst performer: NXP100, NXP200 and NXP900 development drove R&D $27.4M vs $5.8M
  • Cash $140.7M, operating cash use $36.3M, financing cash inflow $145.4M
  • Outlook: cash expected to fund operations through at least 12 months, additional capital required long term

AI summary of the NVCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
  • Exhibit 99.1 contains the substantive results and management update for investor review

Item EX-99.1: Item EX-99.1

  • Third-quarter 2026 results reflect major pipeline expansion, with China approval for ciprocopan and $140.7M cash extending runway into 2H 2029
  • Ciprocopan’s U.S. path remains the key catalyst, with FDA discussions underway and an update expected before year-end
Filed Aug 21, 2026Full analysis →

Item 8.01: Other Events

  • New ATM program enables Nuvectis to sell common shares opportunistically through Jefferies
  • $200 million shelf registration expands potential financing capacity across securities
Filed Aug 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results and corporate update announced for quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing the substantive financial and operating details

Item EX-99.1: Item EX-99.1

  • Q2 net loss $7.0M versus $6.3M; R&D rose to $4.7M from $3.6M as development activity accelerated
  • July follow-on offering raised $115M gross, extending stated cash runway into 1H 2029 but increasing share dilution risk

AI summaries of NVCT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NVCT

Don't miss the next NVCT filing

  • Alerts as it files. A push when NVCT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NVCT, by share count.
  • Ask anything. An AI agent that reads every NVCT filing and answers with sources.

NVCT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Carson Michael J.AAug 3, 2026-
Mosseri Marlio CharlesBuyJun 30, 2026$18.32
BENTSUR RONBuyJun 30, 2026$20.00
Sanchez JuanAJun 11, 2026-
Hoberman KennethAJun 11, 2026-
Kaplan Matthew L.AJun 11, 2026-
Oliviero James F IIIAJun 11, 2026-
BENTSUR RONAJan 6, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$22.9M-$19.8M-$27.6M
Net Income-$22.3M-$19.0M-$26.4M
Balance Sheet
Total Assets$19.2M$18.6M$31.7M
Equity$12.2M$9.7M$18.4M
ROE-182.4%-195.6%-143.6%
Per Share
EPS$-1.43$-1.11$-1.32
Cash Flow
Operating CF-$16.0M-$12.2M-$16.0M

Source: XBRL data in Nuvectis Pharma, Inc. (NVCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NVCT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NVCT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202617$68.0M
Q2 202617$49.3M
Q1 202616$15.7M
Q4 202514$16.0M
Q3 202516$11.4M
Q2 202516$13.0M
Q1 202510$7.7M
Q4 20245$2.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 111 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NVCT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
8-KAug 21, 2026Analysis-
SC 13GAug 6, 2026-
4Aug 5, 2026--
10-QAug 4, 2026Analysis
8-KAug 4, 2026Analysis-
4Jul 1, 2026--
4Jul 1, 2026--
8-KJun 30, 2026Analysis-
8-KJun 29, 2026Analysis-
8-KJun 23, 2026Analysis-
4Jun 12, 2026--
8-KJun 12, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
10-QMay 5, 2026Analysis
8-KMay 5, 2026Analysis-
10-KFeb 11, 2026-
8-KFeb 11, 2026-
4Jan 9, 2026-
4Jan 9, 2026-
4Jan 9, 2026-
4Jan 9, 2026-

Related Health Care companies

All Health Care →

NVCT SEC filings: frequently asked questions

Which institutions hold NVCT stock?

As of September 30, 2026, the largest Nuvectis Pharma, Inc. (NVCT) holders among the 13F filers tracked by SignalX were BlackRock ($27.6 million), Vanguard Capital Management LLC ($19.2 million), State Street Corp ($7.8 million), Northern Trust ($3.6 million), Vanguard Portfolio Management LLC ($3.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did NVCT report in its latest 8-K?

Nuvectis Pharma, Inc. (NVCT) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026.

What are the latest NVCT SEC filings?

Nuvectis Pharma, Inc. (NVCT) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on August 5, 2026.

What is NVCT's SEC CIK number?

Nuvectis Pharma, Inc. (NVCT)'s SEC Central Index Key (CIK) is 1875558. EDGAR lists every NVCT filing under that number.

Ask anything about NVCT

The research agent reads NVCT's filings, financials, insider trades and 13F holders, then answers with sources.